Arkolith/Insider Trading/AVTX/Form 4

Sullivan Christopher Ryan

Chief Financial OfficerAvalo Therapeutics, Inc. (AVTX) · full profile →Form 4 · filed May 1, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$223K
Net Open-Market Flow
-$223K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 30, 2026Sell(S)8K$13.23$112K423
Apr 29, 2026Sell(S)8K$13.09$111K9K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001810417-26-000008) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML